Through the process established by the Centers for Medicare and Medicaid Services (CMS), Micromedex® DRUGDEX® is recognized by CMS as a compendium for the determination of payment for medically‐accepted off‐label indications for anti‐cancer regimens. Effective January 1, 2010, new requirements were implemented that include a provision for providing transparency of processes used to evaluate therapies and to identify potential conflicts of interest. Specifically, publishers of compendia must now make the following information available via their public Web sites1:
1. Provide criteria used to evaluate the request (therapy)
2. Disclose evidence considered
3. Provide names of individuals who have substantively participated in the development of the compendia recommendations and disclose any potential conflicts of interest
4. Provide meeting minutes and records of votes for disposition of the request (therapy)
To meet these requirements, documents detailing this information for each drug/indication pair published on or after January 1, 2010 are posted on this site. Information is organized by drug name, with the document title indicating the off‐label indication.
1Federal Register 2009; 74(226):61901‐61904. http://edocket.access.gpo.gov/2009/pdf/E9‐26502.pdf (accessed March 8, 2010).
Micromedex® and DRUGDEX® are registered trademarks of Truven Health Analytics.
Solutions from Truven Health Analytics are being rebranded as IBM Watson Health